New drug K-CAB Tab. enters Indonesia
Sep.19, 2019
New drug K-CAB Tab. enters Indonesia with No. 1 pharmaceutical company in Southeast Asia
- To supply of finished products to Indonesia for 5 years with KALBE, the No. 1 pharmaceutical company in Southeast Asia
- K-CAB Tab. enters total of 21 countries including Korea, China, Vietnam, Central and South America, and Indonesia
K-CAB Tab., CJ HealthCare's new drug for GERD, is partnering with Southeast Asia's No. 1 pharmaceutical company “KALBE” to target the Indonesian market.
With this export contract, Korea's No. 30 new drug K-CAB tab. has entered into 21 countries including Korea, China, Vietnam, 17 Central and South American countries, and Indonesia.
CJ HealthCare (CEO Kang Seok-Hee) has recently signed a license agreement with Indonesian pharmaceutical company KALBE (CEO Mr. Michael Bujung Nugroho, hereafter 'KALBE') to exclusively supply K-CAB Tab. (ingredient: Tegoprazan), a new drug for GERD, to Indonesia.
Under this contract, CJ HealthCare will supply K-CAB tab. to KALBE for five years after launch, and KALBE will have exclusive sales rights of K-CAB in Indonesia.
Indonesia, where K-CAB will enter, is the fourth most populous country in the world with a population of about 270 million.
The size of the Indonesian pharmaceutical market is 10 trillion and 980 billion won as of 2017, and it has the largest market in the Association of South East Asian Nations (ASEAN). The local GERD treatment market is approximately 120 billion won (in 2017).
KALBE is both Southeast Asia and Indonesia's No.1 pharmaceutical company with annual sales of 1.5 trillion won (in 2017) and currently holds the No. 1 position in the Indonesian GERD treatment (PPI base) market.
K-CAB Tab., a new drug for GERD of a new mechanism of action (P-CAB; potassium competitive acid blocker), was approved as Korea's No. 30 new drug and released in Korea this March.
K-CAB, which recorded a cumulative 10.2 billion won until July, five months after its launch, has recently become a blockbuster drug in the GERD market by adding gastric ulcer as an indication in addition to ERD and NERD.
Kang Seok-Hee, CEO of CJ HealthCare, said, “With this agreement, K-CAB has advanced into 21 countries such as China, Vietnam, 17 Latin American countries, and Indonesia including Korea.” He also said, “as it has received an enthusiastic welcome from patients and medical staff in Korea and recognized its value as a new drug, we hope that it will succeed as a blockbuster in the global market.”